Ticker brief
GMAB
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
33
authors 14d
19
crowd 14d
+1.2σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-14 · now +0.50 (−1 bearish … +1 bullish)
Who spoke19
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 4 | +0.36 |
| @zohmbastic | C | -2.94 | 4 | +0.44 |
| @investseekers | B | +0.02 | 3 | +0.52 |
| @UTEX_io | C | +0.04 | 2 | +0.50 |
| @AlertsAndNews | C | -3.92 | 2 | +0.53 |
| @BiopharmIQ | B | · | 2 | +0.25 |
| @OptionsHawk | B | -1.11 | 2 | +0.58 |
| @cfromhertz | B | -0.96 | 2 | +0.42 |
| @MarketMaestro1 | C | -1.30 | 2 | +0.67 |
| @ACInvestorBlog | C | -4.51 | 1 | +0.45 |
| @HammerstoneMar3 | C | +0.30 | 1 | +0.45 |
| @tenet_research | C | -1.23 | 1 | +0.50 |
| @OptionsFlowBoss | C | · | 1 | +0.50 |
| @OpenOutcrier | C | · | 1 | +0.35 |
| @BabaNeal007 | C | -1.88 | 1 | +0.60 |
| @fwpharma | B | -1.91 | 1 | +0.45 |
| @cnfinancewatch | B | -1.23 | 1 | +0.45 |
| @FXCMOfficial | C | -2.08 | 1 | +0.00 |
| @FwdQuarter | C | · | 1 | +0.25 |
Recent signals30of 33 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-14 | @investseekers | +0.50 | UBS raised GMAB's target to DKK 3,100 after positive trial results and retained confidence. | · | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.00 | Genmab announced third-quarter 2026 net sales for Darzalex without figures in the tweet. | · | tweet ↗ |
| 2026-10-13 | @FwdQuarter | +0.25 | Reports Q3 DARZALEX sales that generate royalties for Genmab. | · | tweet ↗ |
| 2026-10-09 | @BiopharmIQ | +0.35 | Weekly biotech event roundup covering acquisition, clinical data, FDA status, licensing, and a trial miss. | · | tweet ↗ |
| 2026-10-07 | @FXCMOfficial | +0.00 | Lists three weekly hot stocks based on a combined analyst, technical and sentiment score. | · | tweet ↗ |
| 2026-10-07 | @zohmbastic | +0.40 | H.C. Wainwright raised Genmab's target to $50 from $40 and maintained Buy after positive Phase 3 data. | · | tweet ↗ |
| 2026-10-07 | @zohmbastic | +0.40 | Guggenheim raised Genmab's target to $58 from $54 and retained Buy and Top Pick status. | · | tweet ↗ |
| 2026-10-07 | @cnfinancewatch | +0.45 | Publishes a quantitative US-stock technical screen across breakout, base and pullback setups. | · | tweet ↗ |
| 2026-10-06 | @fwpharma | +0.45 | Genmab and AbbVie reported Phase III success for Epkinly in front-line DLBCL. | · | tweet ↗ |
| 2026-10-06 | @UTEX_io | +0.50 | Reports improved survival from an Epkinly lymphoma study and a positive share reaction. | · | tweet ↗ |
| 2026-10-05 | @BabaNeal007 | +0.60 | Celebrates a third party's GMAB call made before a subsequent spike. | · | tweet ↗ |
| 2026-10-05 | @MarketMaestro1 | +0.70 | Celebrates a successful prior GMAB chart call after the move. | · | tweet ↗ |
| 2026-10-05 | @MarketMaestro1 | +0.65 | Explicitly characterizes GMAB as an investment opportunity. | · | tweet ↗ |
| 2026-10-05 | @OzmosiHealth | +0.50 | AbbVie and Genmab reported significant progression-free-survival improvement for an epcoritamab combination. | · | tweet ↗ |
| 2026-10-05 | @OzmosiHealth | +0.50 | Genmab and AbbVie reported statistically significant progression-free-survival improvement. | · | tweet ↗ |
| 2026-10-05 | @OpenOutcrier | +0.35 | Recaps October 5 chatter involving investigations, clinical data, activist pressure, and a lawsuit. | · | tweet ↗ |
| 2026-10-05 | @OptionsFlowBoss | +0.50 | Lists unusually bullish options-volume multiples near the close. | · | tweet ↗ |
| 2026-10-05 | @zohmbastic | +0.35 | Celebrates GMAB reaching the $40 level. | · | tweet ↗ |
| 2026-10-05 | @OptionsHawk | +0.60 | Discloses continued holding of December 30 calls and looks for upside to 50. | · | tweet ↗ |
| 2026-10-05 | @investseekers | +0.50 | Positive Phase III epcoritamab data reduced progression or death risk by 51%. | · | tweet ↗ |
| 2026-10-05 | @tenet_research | +0.50 | AbbVie and Genmab report significant progression-free-survival improvement for an epcoritamab combination. | · | tweet ↗ |
| 2026-10-05 | @cfromhertz | +0.50 | Phase 3 epcoritamab study met its PFS objective and reduced progression or death risk by 51%. | · | tweet ↗ |
| 2026-10-05 | @cfromhertz | +0.35 | Reports a GMAB call trade appearing on the tape. | · | tweet ↗ |
| 2026-10-05 | @HammerstoneMar3 | +0.45 | Genmab and AbbVie report statistically significant PFS improvement for an epcoritamab combination. | · | tweet ↗ |
| 2026-10-05 | @AlertsAndNews | +0.50 | Genmab and AbbVie report statistically significant progression-free-survival improvement. | · | tweet ↗ |
| 2026-10-05 | @zohmbastic | +0.60 | Phase 3 epcoritamab combination met its PFS endpoint with a 51% risk reduction and tolerable safety. | · | tweet ↗ |
| 2026-10-05 | @OptionsHawk | +0.55 | Reports cashing out GMAB for a realized 35% gain. | · | tweet ↗ |
| 2026-10-05 | @BiopharmIQ | +0.15 | Premarket biotech-mover list pairs six leading gains with their stated catalysts. | · | tweet ↗ |
| 2026-10-04 | @AlertsAndNews | +0.55 | Reports durable Phase 2 ovarian-cancer responses, including a 45.9% objective response rate. | · | tweet ↗ |
| 2026-10-04 | @ACInvestorBlog | +0.45 | Reports positive Phase 1/2 ovarian-cancer trial data with response and survival metrics. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.